Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, cohort, real world study of Venetoclax and Hypomethylating agents in newly diagnosed Acute Myeloid Leukemia in the United States

Next Previous
X
Search
Trial Profile

A retrospective, cohort, real world study of Venetoclax and Hypomethylating agents in newly diagnosed Acute Myeloid Leukemia in the United States

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Decitabine (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 03 Nov 2022 Results of real-world venetoclax + HMA treatment practices and outcomes in patients with ND AML in the US, published in the Oncologist
    • 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top